Induced Trf2 deletion leads to aging vascular phenotype in mice associated with arterial telomere uncapping, senescence signaling, and oxidative stress

R. Garrett Morgan\textsuperscript{a}, Ashley E. Walker\textsuperscript{a,b}, Daniel W. Trott\textsuperscript{a,b}, Daniel R. Machin\textsuperscript{a,b}, Grant D. Hens\textsuperscript{a,b,c}, Kelly D. Reih\textsuperscript{a,b}, Richard M. Cawthon\textsuperscript{d}, Eros L. Denchi\textsuperscript{e}, Yu Liu\textsuperscript{a,f}, Samuel I. Bloom\textsuperscript{a}, Tam T. Phuong\textsuperscript{a}, Russell S. Richardson\textsuperscript{a,b,c}, Lisa A. Lesniiewski\textsuperscript{a,b}, Anthony J. Donato\textsuperscript{a,b,g,h},  

\textsuperscript{a}Division of Geriatrics, Department of Internal Medicine, University of Utah School of Medicine, University of Utah, Salt Lake City, UT, USA  
\textsuperscript{b}Geriatric Research, Education, and Clinical Center, George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, UT, USA  
\textsuperscript{c}Department of Exercise and Sport Science, University of Utah, Salt Lake City, UT, USA  
\textsuperscript{d}Department of Human Genetics, University of Utah, Salt Lake City, UT, USA  
\textsuperscript{e}Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA, USA  
\textsuperscript{f}Department of Geriatrics, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China  
\textsuperscript{g}Department of Biochemistry, University of Utah, Salt Lake City, UT, USA  
\textsuperscript{h}Department of Nutrition and Integrative Physiology, University of Utah, Salt Lake City, UT, USA

\textbf{ARTICLE INFO}

\textbf{Keywords:}  
Vascular aging  
Telomeres  
Cellular senescence  
Oxidative stress

\textbf{ABSTRACT}

Age-related vascular dysfunction in large elastic and resistance arteries is associated with reductions in microvascular perfusion and elevations in blood pressure. Recent evidence indicates that telomere uncapping-induced senescence in vascular cells may be an important source of oxidative stress and vascular dysfunction in aging, but the causal relationship between these processes has yet to be elucidated. To test this important unexplored hypothesis, we measured arterial senescence signaling and oxidative stress, carotid and mesenteric artery endothelium-dependent vasodilatory capacity, markers of mesenteric microvascular perfusion and endothelial glycocalyx deterioration, and blood pressure in a novel mouse model of Cre-inducible whole body Trf2 deletion and telomere uncapping. Trf2 deletion led to a 320% increase in arterial senescence signaling ($P < .05$). There was a concurrent 29% and 22% reduction in peak endothelium-dependent vasodilation in carotid and mesenteric arteries, respectively, as well as a 63% reduction in mesenteric microvascular endothelial glycocalyx thickness ($P \leq .01$). Mesenteric microvascular perfusion was reduced by 8% and systolic blood pressure was increased by 9% following Trf2 deletion (both $P < .05$). Trf2 deletion also led to a pro-oxidative arterial phenotype characterized by increased in NADPH oxidase gene expression; a 210% increase in superoxide levels that was partly dependent on NADPH oxidase activity; and an oxidative stress mediated reduction in carotid artery vasodilation (all $P \leq .05$). Collectively, our findings demonstrate that induced Trf2 deletion leads to telomere uncapping, increased senescence signaling, and oxidative stress mediated functional impairments in the vasculature similar to those seen in human aging.

\textbf{1. Introduction}

Advancing age is the primary risk factor for development of vascular functional impairment and cardiovascular disease (CVD) [1]. Endothelial dysfunction in large elastic and resistance arteries is an important age-associated alteration that contributes to reduced microvascular perfusion and elevated blood pressure in older adults [2–5]. Hallmarks of age-related endothelial dysfunction, such as reduced bioavailability of the endothelium-derived vasodilator nitric oxide (NO), impaired endothelium-dependent vasodilation, and degradation of the endothelial glyocalyx (a proteoglycan/glycoprotein layer lining endothelial cells) [6], are due in large part to the accumulation of reactive oxygen species (ROS) like superoxide [7–9]. In vitro studies in multiple cell types demonstrate that tumor suppressor protein p53 (p53)-induced senescence leads to increased cellular production and release of ROS generated through increased NADPH oxidase activity...
and reduced superoxide dismutase activity [12]. Thus, the accumulation of senescent vascular cells with advancing age may be an important mediator of ROS-induced vascular dysfunction. Indeed, our group has recently documented an age-associated upregulation of the p53-induced senescence marker, cyclin-dependent kinase inhibitor 1A (p21), in human endothelial cells and demonstrated its link with endothelial dysfunction [13]. Characterization of the mechanisms that lead to the accumulation of senescent cells in the aging vasculature could prove to be critically important to our understanding of age-associated endothelial dysfunction and CVDs.

Telomere dysfunction is a key age-related process that could lead to cellular senescence, ROS overproduction, and subsequent impairments in vascular function. Telomeres are composed of TTAGGG repeats that form the natural ends of chromosomes and—along with telomere binding proteins like telomeric repeat binding factor 2 (Trf2)—generate specialized structures known as t-loops that prevent chromosome ends from being recognized as double-strand (ds) DNA breaks by the DNA damage repair machinery [14,15]. Indeed, experimental knockdown of Trf2 leads to breakdown of the t-loop structure, referred to as telomere uncapping, and initiates a rapid dsDNA break response, p53-mediated upregulation of p21, and cellular senescence [14,16]. Telomere shortening occurs over time in most tissues, which may lead to critically short telomeres and subsequent uncapping [17,18]. Alternatively, ROS-mediated damage to telomeric DNA or dysregulation of telomere binding proteins may lead to age-related uncapping without the need for exceptionally short telomeres.

Currently, we have limited observational evidence for the role of telomere uncapping in p53-induced senescence within the human vasculature. These findings suggest that uncapping leads to p53-induced senescence in arteries with advancing age and impaired blood pressure regulation [19,20]. Despite clear evidence of age-related arterial telomere shortening, age- and hypertension-associated uncapping occurs independent of telomere length [19,20]. Furthermore, telomere uncapping is correlated with p53-induced senescence while telomere length is not [19,20]. Importantly, these previous studies demonstrated clear associations between these factors, but did not mechanistically establish telomere uncapping as a cause of age- and hypertension-associated vascular phenotypes. Therefore, an important untested model of human vascular aging predicts that telomere uncapping leads to cellular senescence and elevated ROS in the vasculature, which results in micro- and macrovascular dysfunction.

In the present study, we hypothesized that Trf2 deletion results in reduced microvascular perfusion and elevated blood pressure by triggering telomere uncapping, senescence signaling, and ROS-mediated endothelial dysfunction in conduit and resistance arteries. To test this hypothesis, we measured specific markers of arterial p21-induced senescence, carotid and mesenteric artery endothelium-dependent vasodilatory capacity, markers of microvascular perfusion and glycocalyx deterioration, blood pressure, and several key mediators of arterial oxidative stress in a novel mouse model of Cre-inducible whole body Trf2 deletion mediated telomere uncapping [21].

2. Materials and methods

2.1. Animals

Conditional whole body deletion of floxed exons 1 and 2 of the Trf2 gene was used to induce telomere uncapping in adult mice (aged 4–5 months). Mice that expressed Cre-recombinase in all tissues under control of the tamoxifen-inducible estrogen receptor T2 (CreER) moiety were crossed with mice homozygous for floxed Trf2 (Trf2f/f) [21] and wild type Trf2 (Trf2+/+) to create compound Trf2f/+ + CreER and Trf2+/+ + CreER mice for use as Trf2 deficient experimental animals and wild type controls, respectively. Trf2f/+ mice were derived from the same litters as selected Trf2f/+ mice to ensure that the final Cre-expressing experimental and wild type control animals had identical compound genetic backgrounds. Trf2f/- + CreER mice were generated by inducing Cre-recombinase mediated deletion of Trf2f/- in all tissues of Trf2f/+ + CreER mice with daily intraperitoneal injections of tamoxifen (1 mg/day) for a total of 4–8 days depending on animal body weight (total tamoxifen given = 200 mg-tamoxifen/kg) [22]. Importantly, both Trf2f/+ + CreER mice and Trf2f/+ + CreER wild type control mice were injected with identical tamoxifen treatment regimens to control for the effect of tamoxifen in all subsequent analyses (hereafter tamoxifen treated animals are denoted as Trf2f/- + CreER-POST and Trf2f/+ + CreER-POST mice). Animal breeding and care procedures described in detail in Online Supplement.

2.2. Arterial Trf2 deletion, telomere uncapping, and telomere length

Arterial Trf2 mRNA expression was determined by qRT-PCR; arterial Trf2 protein by western blot; arterial telomere uncapping by chromatin immunoprecipitation (ChIP); and arterial telomere length by a sequence independent multiplex qPCR technique, as previously described in detail [19] and outlined in Online Supplement.

2.3. Arterial p21-induced senescence signaling markers

p21 protein expression was assessed by fluorescence microscopy in carotid arteries, and arterial p21 and the ARF variant of cyclin-dependent kinase inhibitor 2A (p19ARF) mRNA expression by qRT-PCR, as outlined in detail in Online Supplement.

2.4. Carotid and mesenteric artery endothelium-dependent vasodilation: modulation by NO and superoxide

Measurements of endothelial-dependent and endothelial-independent vasodilatory capacity in isolated carotid and mesenteric arteries (2nd order arteries isolated from mesenteric region), and measurements of vasconstrictor function and myogenic tone in mesenteric arteries, were made using an ex vivo method previously described in detail [8] and outlined in Online Supplement.

2.5. Mesenteric microvascular endothelial glycocalyx function and perfusion

Mesenteric microvasculature perfusion, microvessel density, and endothelial glycocalyx function and thickness were measured using a recently validated intravital microscopy technique as previously described in detail [6] and outlined in Online Supplement.

2.6. Blood pressure

2–3 days before and immediately after completing tamoxifen treatment, systolic blood pressure (SBP) was assessed noninvasively in conscious mice by determining the tail blood volume with a volume pressure recording (VPR) sensor and occlusion tail-cuff (CODA System, Kent Scientific) as previously described in detail [6] and outlined in Online Supplement.

2.7. Arterial oxidative stress markers

Arterial NADPH oxidase 1, 2, and 4 (Nox1, Nox2, and Nox4) and superoxide dismutase 1–3 (Sod1, Sod2, and Sod3) mRNA expression was determined by qRT-PCR, and superoxide content was assessed by CMH spin probe and electron paramagnetic resonance spectrometry with and without apocynin and plumbagin mediated Nox activity inhibition, as previously described [8,23] and outlined in detail in the Online Supplement.
2.8. Statistics

Group mean differences were tested by unpaired and paired sample t-tests with equal variances assumed or multi-factorial ANOVAs with Tukey’s post-hoc tests. For all dose response and automated capture and analysis measures, group mean differences were tested by two-way repeated-measures ANOVAs with Fisher’s LSD post-hoc tests. Alpha was set at \( P < .05 \) and all analyses were completed using GraphPad Prism version 6.0.

3. Results

3.1. Trf2 deletion leads to arterial telomere uncapping with no change in telomere length

Tamoxifen induced Cre-recombinase activation resulted in \( \text{loxP} \) directed deletion of floxed exons 1 and 2 of the \( \text{Trf2} \) gene in arterial tissue from \( \text{Trf2}^{+/+} + \text{CreER} \) mice (Fig. 1A). \( \text{Trf2} \) deletion resulted in an 85% knockdown of arterial \( \text{Trf2} \) mRNA expression in \( \text{Trf2}^{-/-} + \text{CreER-POST} \) mice as compared with \( \text{Trf2}^{+/+} + \text{CreER-POST} \) mice (\( P = .01; \) Fig. 1B). We confirmed that \( \text{Trf2} \) deletion and knockdown of \( \text{Trf2} \) mRNA expression led to a respective 58% and 42% knockdown of \( \text{Trf2} \) protein in a small subset of aortic and mesenteric artery samples from \( \text{Trf2}^{-/-} + \text{CreER-POST} \) mice as compared with those from \( \text{Trf2}^{+/+} + \text{CreER-POST} \) mice (both \( P < .01; \) Supplemental Fig. S1A+B). Accordingly, \( \text{Trf2} \) knockdown in \( \text{Trf2}^{-/-} + \text{CreER-POST} \) mice led to a 55% increase in arterial telomere uncapping as compared with \( \text{Trf2}^{+/+} + \text{CreER-POST} \) mice (\( P < .05; \) Fig. 1C). Arterial telomere uncapping in \( \text{Trf2}^{-/-} + \text{CreER-POST} \) mice occurred without a change in telomere length (\( P = .48; \) Fig. 1D). The level of observed vascular telomere uncapping roughly corresponds to that seen in late middle-aged or early older adult humans (55–60 years of age) [19]. Thus, our whole body \( \text{Trf2} \) deletion system produced an experimental model that was largely representative of the vascular telomere uncapping observed with advancing age in humans.

3.2. Trf2 deletion leads to reductions in body weight and adipose tissue

There was no difference in body weight between \( \text{Trf2}^{+/+} + \text{CreER} \) and \( \text{Trf2}^{+/+} + \text{CreER} \) mice prior to Cre-recombinase activation.

Fig. 1. \( \text{Trf2} \) gene deletion and arterial telomere uncapping. Representative DNA gel images with genotype-specific PCR products (cropped to shape) and diagram demonstrating \( \text{loxP} \) directed deletion of exons 1 and 2 from \( \text{Trf2} \) gene in arterial tissue from \( \text{Trf2}^{+/+} + \text{CreER} \) mice (A). Arterial \( \text{Trf2} \) mRNA expression (B), telomere uncapping (C), and telomere length (D) in \( \text{Trf2}^{+/+} + \text{CreER-POST} \) and \( \text{Trf2}^{-/-} + \text{CreER-POST} \) mice (\( n = 6–11 \) per group). mRNA is expressed relative to 18 s rRNA expression to account for differences in total RNA. ChIP data is expressed relative to input telomeric DNA content to account for differences in cell number. Data presented are means ± SEM normalized to \( \text{Trf2}^{+/+} + \text{CreER-POST} \) mean. *\( P < .05 \) and **\( P = .01 \) vs. \( \text{Trf2}^{+/+} + \text{CreER-POST} \) mice. Terms: \( \text{Trf2} \), telomeric repeat binding factor 2; \( \text{CreER} \), Cre-recombinase associated with estrogen receptor T2; POST/POST Tam TX, post tamoxifen treatment; ex, exon; bp, base pair; F/F, homozygous floxed allele; \( \gamma \)-H2, p-histone \( \gamma \)-H2A.X (ser139); and T/S, telomeric DNA/single copy gene signals.
Similarly, there was no body weight difference among Trf2+/+ + CreER mice before and after Cre activation (P = .48). A 15% reduction in body weight was observed between Trf2F/F + CreER mice and the resulting Trf2−/− + CreER-POST mice after Cre activation and Trf2 deletion (P < .01), and final body weight was 21% lower in Trf2−/− + CreER-POST mice than that of Trf2+/+ + CreER-POST mice (P < .0001; Supplemental Table S1). Absolute heart, liver, quadriceps, and epididymal white adipose tissue (WAT) weights in Trf2−/− + CreER-POST mice were lower than those of Trf2+/+ + CreER-POST mice (all P < .02; Supplemental Table S1). However, when normalized for final body weight, only WAT weight in Trf2−/− + CreER-POST mice was lower than that of Trf2+/+ + CreER-POST mice (P < .01, Supplemental Table S1).

### 3.3. Trf2 deletion leads to arterial p21-induced senescence signaling

Trf2 deletion led to a 320% increase in p21 positive cells and 330% increase in p21 mRNA expression in arterial tissue (both P ≤ .03; Fig. 2A+B) in Trf2−/− + CreER-POST mice as compared with that from Trf2+/+ + CreER-POST mice. To rule out the influence of p53 activation and subsequent p21 up-regulation that may have occurred independent of Trf2 deletion and telomere uncapping, we measured the expression of p19ARF, which is a p53 activating protein that is responsive to cellular stress signals in mammalian cells, but not DNA damage response signaling [24]. There was no difference in arterial p19ARF mRNA expression between Trf2−/− + CreER-POST and Trf2+/+ + CreER-POST mice (P = .33; Fig. 2C).

### 3.4. Trf2 deletion leads to impaired endothelium-dependent vasodilatory capacity in carotid and mesenteric arteries

Endothelium-dependent dilation (EDD) in response to the endothelium-specific vasodilator, acetylcholine (ACh), was reduced in isolated carotid and mesenteric arteries from Trf2−/− + CreER-POST mice as compared with those from Trf2+/+ + CreER-POST mice (31% and 22% reduction in max dilation, respectively; both P < .01; Fig. 3A+B). Incubation with NG-nitro-L-arginine methyl ester (LNAME), a non-selective endothelial nitric oxide synthase inhibitor, did not further reduce EDD to ACh in carotid or mesenteric arteries from Trf2−/− + CreER-POST mice (both P ≥ .17 vs. ACh alone; Fig. 3A+B), but reduced that in carotid and mesenteric arteries from Trf2+/+ + CreER-POST mice (22% and 52% reduction in max dilation vs. ACh alone, respectively; both P < .001; Fig. 3A+B). This abolished the group difference in vasodilatory response to ACh in both artery types (both P ≥ .54), which demonstrates that the EDD impairment observed in Trf2−/− + CreER-POST mice was NO-dependent. The reduction in peak EDD to ACh in the presence of LNAME (max dilation to ACh minus

![Fig. 2. Trf2 deletion and arterial p21-induced senescence signaling. Arterial p21 positive cells (A), p21 mRNA expression (B), and p19ARF mRNA expression (C) in Trf2+/+ + CreER-POST and Trf2−/− + CreER-POST mice (n = 3–8 per group). mRNA is expressed relative to 18 s rRNA expression to account for differences in total RNA. p21 positive cells are expressed relative to DAPI nuclear staining signal to account for differences in cell number. Representative images of carotid artery lamina auto-fluorescence (FITC channel), DAPI staining (DAPI channel), p21 protein staining (Cy5 channel), and merged image shown next to panel (A) (images cropped to shape; scale bars = 100 μm). Relative size of arteries shown is not representative of mean difference in carotid artery diameter between groups (see Results Section 3.4). Data presented are means ± SEM normalized to Trf2+/+ + CreER-POST mean. * P < .05 vs. Trf2+/+ + CreER-POST mice. Terms: p21, cyclin-dependent kinase inhibitor 1A (p21); p19ARF, cyclin-dependent kinase inhibitor 2A (ARF variant); Trf2, telomeric repeat binding factor 2; CreER, Cre recombinase associated with estrogen receptor T2; POST/POST Tam TX, post tamoxifen treatment; and DAPI, 4′,6-diamidino-2-phenylindole.

max dilation to ACh + LNAME), which represents NO-mediated vasodilation, was 24% lower in carotid arteries and 26% lower in mesenteric arteries from Trf2\(^{-/-}\)+CreER-POST mice than those from Trf2\(^{+/+}\)+CreER-POST mice (both \(P \leq .01\); Fig. 3C+D).

There was no difference in carotid or mesenteric artery dilation to the endothelium-independent vasodilator, sodium nitroprusside, between Trf2\(^{-/-}\)+CreER-POST and Trf2\(^{+/+}\)+CreER-POST mice (both \(P \geq .50\); Fig. 3E+F), which suggests the group difference in EDD was not due to vascular smooth muscle dysfunction. Furthermore, we found no difference in maximum carotid artery diameter between Trf2\(^{-/-}\)+CreER-POST and Trf2\(^{+/+}\)+CreER-POST mice, as determined by passive distention response to increasing intraluminal pressure (448.0 ± 16.4 μm vs 448.4 ± 19.9 μm, respectively; \(P = .49\)). There was no group difference in mesenteric artery constriction in response to the \(\alpha\)-adrenergic agonist, phenylephrine (PE)\(^{-}\)max constriction to PE in Trf2\(^{-/-}\)+CreER-POST mice: 45.0 ± 8.2% vs. Trf2\(^{+/+}\)+CreER-POST mice: 43.0 ± 8.3%; \(P = .79\), which demonstrates that the mesenteric artery EDD impairment observed in Trf2\(^{-/-}\)+CreER-POST mice was not due to increased sensitivity to adrenergic signaling. To confirm that the selected mesenteric arteries were indeed 2nd order mesenteric arteries capable of generating myogenic tone, we measured spontaneous tone in each group. Mesenteric arteries from Trf2\(^{-/-}\)+CreER-POST mice had a starting diameter of 163 ± 7 μm and maximum diameter of 206 ± 6 μm, while those from Trf2\(^{-/-}\)+CreER-POST mice had a
starting diameter of 150 ± 6 μm and maximum diameter of 191 ± 5 μm, which represents a respective myogenic tone capacity of 20 ± 3% and 21 ± 2%. Myogenic tone capacity was not different between groups (P = .63).

3.5. Trf2 deletion leads to impaired mesenteric microvascular perfusion and endothelial glycocalyx deterioration

Microvascular perfusion, assessed by measuring the red blood cell (RBC) fraction across a range of mesenteric microvessel diameters with an automated capture and analysis system, was reduced by 11% in Trf2−/− + CreER-POST mice as compared with Trf2+/+ + CreER-POST mice (P = .03; Fig. 4A+B), despite no group difference in total mesenteric microvessel density (3841 ± 290 vs. 4298 ± 193 μm²/mm², respectively; P = .12). Likewise, Trf2 deletion led to a 41% reduction in total perfused microvessel density (Trf2−/− + CreER-POST mice: 1681 ± 139 μm²/mm² vs. Trf2+/+ + CreER-POST mice: 2871 ± 144; P < .0001). Mesenteric microvascular endothelial glycocalyx dysfunction was assessed by measuring the depth of RBC penetration into the endothelial glycocalyx (termed perfused boundary region) across a range of mesenteric microvessel diameters utilizing the same automated system. There was a 20% increase in the perfused boundary region of Trf2−/− + CreER-POST mice as compared with Trf2+/+ + CreER-POST mice (P = .02; Fig. 4C+D), which signifies endothelial glycocalyx deterioration in Trf2−/− + CreER-POST mice. Accordingly, using a separate manual method to assess glycocalyx
thickness, there was a 63% reduction in endothelial glyocalyx thickness in mesenteric microvessels in \( \text{Trf2}^{-/-} + \text{Cre-ER-POST} \) mice as compared with \( \text{Trf2}^{+/+} + \text{Cre-ER-POST} \) mice (0.34 ± 0.07 vs. 0.92 ± 0.07 \( \mu \)m, respectively; \( P < .0001 \)).

### 3.6. Trf2 deletion leads to increased blood pressure

SBP increased by approximately 11 mmHg following Trf2 deletion in \( \text{Trf2}^{++/} + \text{Cre-ER} \) mice (\( P < .05 \); Fig. 4E), while SBP did not change following Cre-recombinase activation in \( \text{Trf2}^{+/+} + \text{Cre-ER-POST} \) mice (\( P \geq .43 \); Fig. 4E). Heart rate decreased at post-testing in both \( \text{Trf2}^{-/-} + \text{Cre-ER-POST} \) and \( \text{Trf2}^{+/+} + \text{Cre-ER-POST} \) mice (both \( P < .05 \); Fig. 4F), but there was no group difference in final heart rate (\( P = .25 \); Fig. 4F). This indicates that increased heart rate and/or altered autonomic nervous system function were not responsible for the observed changes in blood pressure and group differences in microvascular perfusion.

### 3.7. Trf2 deletion leads to a pro-oxidative arterial phenotype and ROS-mediated endothelial dysfunction in carotid arteries

We found 28% and 186% increases in Nox2 and Nox4 mRNA expression, respectively, in arterial tissue from \( \text{Trf2}^{-/-} + \text{Cre-ER-POST} \) mice as compared with that from \( \text{Trf2}^{+/+} + \text{Cre-ER-POST} \) mice (both \( P < .05 \); Fig. 5A). Arterial Nox1 mRNA expression was not different between \( \text{Trf2}^{-/-} + \text{Cre-ER-POST} \) mice and \( \text{Trf2}^{+/+} + \text{Cre-ER-POST} \) mice (\( P = .14 \); Fig. 5A). Likewise, mRNA expression of the antioxidant enzymes, Sod1, Sod2, and Sod3, in arterial tissue from \( \text{Trf2}^{-/-} + \text{Cre-ER-POST} \) mice was not different as compared with that from \( \text{Trf2}^{+/+} + \text{Cre-ER-POST} \) mice (all \( P \geq .6 \); Fig. 5B).

There was also a 210% increase in superoxide levels in arterial tissue from \( \text{Trf2}^{-/-} + \text{Cre-ER-POST} \) mice as compared with that from \( \text{Trf2}^{+/+} + \text{Cre-ER-POST} \) mice (\( P < .01 \); Fig. 5C). In a small subset of samples, we treated arterial tissue with the non-selective Nox inhibitor, apocynin, and SOD4 inhibitor, plumbagin, prior to assessment of superoxide levels. Superoxide levels remained 2.6 to 4.4 fold higher in arterial tissue from \( \text{Trf2}^{-/-} + \text{Cre-ER-POST} \) mice than that from \( \text{Trf2}^{+/+} + \text{Cre-ER-POST} \) mice following treatment with either apocynin or plumbagin, but were reduced by 65% and 32% in \( \text{Trf2}^{-/-} + \text{Cre-ER-POST} \) mice, respectively, compared with vehicle treatment (all \( P < .05 \); Supplemental Fig. S2). This exploratory result indicates that elevated superoxide content in arteries following Trf2 deletion was mediated in part by NADPH oxidase activity.

Incubation of carotid arteries with 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-oxyl (TEMPOL), a superoxide scavenger, restored EDD to ACh in \( \text{Trf2}^{+/+} + \text{Cre-ER-POST} \) mice (both \( P < .05 \); Fig. 5D), which demonstrates that the observed reduction in carotid artery EDD in \( \text{Trf2}^{-/-} + \text{Cre-ER-POST} \) mice was dependent on superoxide activity. Incubation with LNAME in the presence of TEMPOL abolished the selective TEMPOL-

---

![Fig. 5. Trf2 deletion, pro-oxidative arterial phenotype, and ROS-mediated arterial endothelial dysfunction.](image-url)

Arterial Nox1, Nox2, and Nox4 mRNA expression (A); Sod1, Sod2, and Sod3 mRNA expression (B); superoxide content (C); and vasodilatory response of carotid arteries to max dose of ACh alone and after pretreatment with NO synthase inhibitor LNAME in the absence or presence of superoxide scavenger TEMPOL (D) in \( \text{Trf2}^{+/+} + \text{Cre-ER-POST} \) and \( \text{Trf2}^{-/-} + \text{Cre-ER-POST} \) mice (\( n = 4-15 \) per group). mRNA is expressed relative to 18s rRNA expression to account for differences in total RNA, and mRNA expression and superoxide content presented normalized to \( \text{Trf2}^{+/+} + \text{Cre-ER-POST} \) mean. Representative EPR generated CMH signal curves used to calculate superoxide content shown below panel and cropped to shape (C). Data presented are means ± SEM. *\( P < .05 \), **\( P < .01 \), and ***\( P < .001 \) vs. \( \text{Trf2}^{+/+} + \text{Cre-ER-POST} \) mice; *\( P < .05 \) vs. ACh alone within group; and *\( P < .05 \) vs. ACh + TEMPOL within group. Terms: ROS, reactive oxygen species; Trf2, telomeric repeat binding factor 2; Cre, Cre-recombinase associated with estrogen receptor T2; POST/POST Tam TX, post tamoxifen treatment; Nox, NADPH oxidase; Sod, superoxide dismutase; NO, nitric oxide; EPR, electron paramagnetic resonance; and CMH, 1-hydroxy-3-methoxycarbonyl-2,2,5,5-tetramethylpyrroline-3-one; ACh, acetylcholine; LNAME, N\(^{-}\)-nitro-L-arginine methyl ester; and TEMPOL, 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-oxyl.
mediated restoration of EDD to ACh in Trf2−/− + CreER-POST mice and EDD response to ACh in Trf2+/+ + CreER-POST mice (both P ≤ .01 vs. ACh + TEMPO; Fig. 5D). There was no group in EDD to ACh difference following TEMPO+LNAME treatment (P = .51; Fig. 5D). These results demonstrate that superoxide consumption of NO mediates impaired carotid artery EDD in Trf2−/− + CreER-POST mice.

4. Discussion

The key novel findings are as follows: First, Cre-induced whole body Trf2 deletion in mice leads to arterial telomere uncapping and p21-induced senescence signaling without changes in telomere length, thus establishing an experimental system that models arterial telomere uncapping in human aging. Next, we demonstrated that Trf2 deletion leads to micro- and macro-vascular dysfunction similar to that seen in human aging. The observed dysfunction is characterized by attenuated endothelium-dependent vasodilation in carotid and mesenteric arteries, reduced mesenteric microvascular perfusion and microvascular endothelial glycocalyx deterioration, and increased systolic blood pressure. Last, Trf2 deletion leads to a pro-oxidative arterial phenotype characterized by increased NADPH oxidase gene expression; increased superoxide levels, mediated in part by NADPH oxidase activity; and superoxide-mediated suppression of carotid artery endothelium-dependent vasodilation. Collectively, our findings demonstrate that experimentally induced Trf2 deletion in mice leads to oxidative stress mediated functional impairments in the vasculature that phenocopy those seen in human aging.

4.1. Telomere uncapping, p21-induced senescence signaling, and senescence-associated oxidative stress in the vasculature

Telomere uncapping and cellular senescence may be important upstream processes that lead to functional impairments in the vasculature. Prior studies have clearly shown that experimentally induced telomere uncapping leads to p53/p21-induced senescence in multiple cell types and tissues, including vascular cells [14,16,21,25]. The present study, however, is the first to provide evidence that Trf2 deletion induced in vivo leads to telomere uncapping and p21-induced senescence signaling in an otherwise normal vasculature. Here we demonstrate that whole body deletion of Trf2 results in increased arterial p21 gene expression and protein upregulation that occurs without a change in telomere length or p19ARF expression. p19ARF activates p53 in response to strong mitogenic signals, but not in response to DNA damage or telomere uncapping [24]. Thus, the observed increase in p21 expression was likely due directly to telomere uncapping and not from any indirect cell signaling effects. These findings provide proof of concept that Trf2 deletion and resulting telomere uncapping could lead to upregulation of p21-induced senescence markers in arteries, which supports the available observational evidence in humans for a link between arterial telomere uncapping and p53-induced senescence in the context of aging and CVD. Future studies, utilizing p53-null mice or in vitro p53 knockdown experiments, are required to conclusively establish a causal relationship between Trf2 deletion, p53 and vascular functional impairment.

4.2. Trf2 deletion and oxidative stress mediated vascular dysfunction

The release of ROS from senescent cells that accumulate in the vasculature over time could lead to impaired vascular function and contribute to age- and disease-associated phenotypes. In the present study, we demonstrated that Trf2 deletion leads to higher Nox2/4 gene expression and increased superoxide levels in arteries concomitant with p21-induced senescence signaling. A set of exploratory experiments that we conducted indicate that the Trf2 deletion induced increase in superoxide levels is mediated in part by NADPH oxidase activity. The specific goal of this study was to establish a causal relationship between Trf2 deletion and vascular dysfunction, and not to provide a comprehensive assessment of all pathways that mediate this relationship. However, we believe these findings support our hypothesis that telomere uncapping mediated senescence leads to a pro-oxidative vascular phenotype that is characterized by increased superoxide production mediated in part by increased NADPH oxidase expression.

Evidence from human and animal studies clearly demonstrates that ROS-mediated consumption of NO leads to reduced NO bioavailability and impaired endothelium-dependent vasodilation in aging [8,9]. Rapid deterioration of the endothelial glycocalyx occurs as a result of ROS accumulation in the vasculature, and can further exacerbate vasodilatory impairments by altering NO release [26,27]. Here we demonstrate that Trf2 deletion leads to reduced endothelium-dependent vasodilatory capacity in carotid and mesenteric arteries. These impairments occurred without evidence of vascular smooth muscle or vasoconstrictor dysfunction, as demonstrated by intact vasodilatory responses to an endothelium-independent dilator (SNP) and α-adrenergic agonist (PE). That said, we cannot rule out the potential influence of other aspects of smooth muscle function that may be impaired following Trf2 deletion and telomere uncapping. We further demonstrate that Trf2 deletion mediated impairments in vasodilatory capacity are due to reduced NO bioavailability in both artery types and that the reduction in NO bioavailability in carotid arteries was the result of ROS-mediated consumption of NO. We also assessed mesenteric microvascular glycocalyx function using a recently validated automated capture and analysis system that measures the thickness of the glycocalyx layer and the extent of RBC encroachment into the vessel wall due to thinning of the glycocalyx [6]. Utilizing this system we found clear evidence of a diminished endothelial glycocalyx layer similar to that seen in normal vascular aging [6].

Impaired endothelium-dependent vasodilation can lead to increased local vascular tone, which can in turn reduce blood flow to the microvasculature [5] and elevate systolic blood pressure as a consequence of developing less compliant conduit and blood pressure regulating resistance arteries [2–4,28]. Furthermore, endothelial glycocalyx dysfunction can independently mediate blood pressure dysregulation by disrupting sodium resorption through the microvascular endothelium [27,29]. Here we found that Trf2 deletion led to reduced perfusion in the mesenteric microvasculature despite no change in total microvascular density. Trf2 deletion also led to increased systolic blood pressure, which supports recent observational evidence in humans linking arterial telomere uncapping, p53-induced senescence, and hypertension [20]. Interestingly, heart rate decreased during post-testing in both Trf2−/− + CreER-POST and Trf2+/+ + CreER-POST mice, which may have been the result of tamoxifen induced bradycardia as observed in some human case studies [30,31]. The observed change in blood pressure, however, was relatively modest and did not lead to clinical hypertension in our experimental animals. Importantly, this effect on blood pressure occurred without the influence of other cardiovascular insults. In the context of normal aging, older adults accumulate uncapped telomeres within their vascular cells along with a variety of other age-related vascular changes not associated with telomere dysfunction. Collectively, these factors contribute to the typical magnitude of blood pressure increase seen in normal human aging. Thus, these results may demonstrate the independent influence of telomere uncapping on blood pressure.

4.3. Experimental considerations

While tissue-specific Trf2 deletion models would demonstrate the functional effects of telomere uncapping in different vascular cell types, age- and disease-associated telomere uncapping may occur in a variety of cellular sources that impact vascular function, including endothelial cells, vascular smooth muscle cells, and immune cells. Thus, we believe the selected model of inducible whole body Trf2 deletion provides the most accurate representation of in vivo telomere uncapping in humans.
and its downstream effects in the vasculature. Likewise, current evidence for vascular telomere uncapping in humans is limited to data generated from whole artery tissue samples rather than that from specific vascular cell types. Therefore, we focused our experimental outcomes on vascular function endpoints and whole artery assays to better model the design of relevant human tissue studies and provide the most direct test of our stated hypothesis. We believe this experimental system was the most appropriate choice for this initial proof of concept study; however, future studies may utilize tissue-specific Trf2 deletion models to determine the relative contributions of different vascular cell types to the observed phenotypes.

5. Conclusions

The overall aim of this study was to determine if experimentally induced Trf2 deletion in mice results in phenotypic changes and functional outcomes in the vasculature similar to those seen in human aging. Our findings demonstrate that Trf2 deletion leads to arterial telomere uncapping and p21-induced senescence signaling, endothelial dysfunction in carotid and mesenteric arteries, mesenteric microvascular perfusion impairments, and increased systolic blood pressure. These findings also demonstrate that Trf2 deletion mediates vascular dysfunction through a pro-oxidative arterial phenotype and ROS-mediated impairments in endothelial function. We believe this study provides the mechanistic foundation for future studies aimed at establishing the prognostic value of telomere uncapping as a biomarker for vascular aging and CVD. Furthermore, these findings have revealed novel pathways involved in telomere uncapping associated vascular dysfunction, which may lead to the identification of pharmacological and/or behavioral interventions that can slow or reverse age-associated vascular dysfunction.

Supplementary data to this article can be found online at https://doi.org/10.1016/j.jymcc.2018.11.014.

Funding sources

This work was supported by the National Institutes of Health (R01AG040297, R01AG050238, R44AG053131, R21AG037355, K01AG046326, and K02AG045339).

Disclosure and conflict of interest

Dr. Cawthon did not conduct any telomere length measurements for this study, but his patented telomere length measuring technology has been licensed to Telomere Diagnostics, Inc. of Menlo Park, California. No other authors have disclosures or conflicts of interests to report.

Acknowledgements

R. Garrett Morgan and Anthony J. Donato contributed to all aspects of the study, while remaining authors contributed to the collection and analysis of data, and revision of this manuscript. Eros L. Denchi, Richard M. Cawthon, and Russell S. Richardson further contributed essential reagents and analytical tools.

References